Neopterin and the risk of dementia in persons with Down syndrome

Tonnie Coppus, Durk Fekkes, Willem Verhoeven, Evenhuis, Cornelia Duijn

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)

Abstract

Persons with Down syndrome show an altered immune response and an increased susceptibility to Alzheimer's disease. In a prospective study, we examined whether the plasma neopterin level, a marker for cell-mediated immune activation and inflammation, is associated with an increased risk of dementia in persons with Down syndrome. Plasma concentrations of neopterin were determined in a population-based study of 394 persons with Down syndrome, who were screened annually for dementia. We used Cox proportional hazards model to determine risk of dementia. Demented persons with Down syndrome have a significantly (p=0.05) higher plasma neopterin concentration than the non-demented. In the non-demented without autoimmune disorders, in those with a plasma level of neopterin above median, the risk to develop dementia increased to 1.83 (95% confidence interval: 1.04-3.20). High plasma neopterin level is an independent determinant of the risk of dementia in persons with Down syndrome. (c) 2009 Elsevier Ireland Ltd. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)60-64
Number of pages5
JournalNeuroscience Letters
Volume458
Issue number2
DOIs
Publication statusPublished - 2009

Research programs

  • EMC NIHES-01-64-02
  • EMC NIHES-02-67-01
  • EMC ONWAR-01-94-01
  • EMC OR-01-58-01

Cite this